Gynecologic Cancers

A presentation at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting shared updated findings on the efficacy of lenvatinib plus pembrolizumab in patients with advanced endometrial cancer.

An expert from NYU Langone outlines how checkpoint blockade approvals have helped advance endometrial cancer management.

Inguinofemoral radiotherapy may be a safe alternative for patients with vulvar cancer and sentinel node micrometastases who might otherwise face the morbidity of a lymphadenectomy.

Pembrolizumab is approved both in combination with chemotherapy, with or without bevacizumab, and as a single agent for the treatment of patients with recurrent or metastatic cervical cancer.

Combining immunotherapy with other targeted therapies may result in more promising outcomes than immunotherapy alone in the treatment of recurrent ovarian cancer, according to an expert at University of California, Los Angeles.

New research suggests that fertility-sparing surgery is feasible and safe in treating ovarian malignant germ cell tumors.

A new retrospective cohort found that women who had received the human papillomavirus vaccine had similar rates of primary ovarian insufficiency as unvaccinated women.

Loop electrical excision procedure (LEEP) demonstrated superior capabilities in clearing high-risk HPV infections in women with cervical intraepithelial neoplasia (CIN2+).

The FDA has granted cemiplimab-rwlc a priority review based on findings from the largest to-date, randomized clinical trial in advanced cervical cancer.

A phase 2 trial presented at the 2021 ESMO Annual Congress showed that Balstilimab plus Zalifrelimab induced superior response rates, duration of responses, and overall survival in patients with recurrent/metastatic cervical cancer.

Data presented at the 2021 ESMO Congress suggest that pembrolizumab in addition to chemo with or without bevacizumab may become new standard of care in the frontline setting of cervical cancer treatment.

Rechallenge with maintenance olaparib following response to platinum-based chemotherapy significantly improved PFS in heavily pretreated patients with relapsed ovarian cancer.

The FDA approved tisotumab vedotin for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

Interim findings presented at the 2021 ESMO congress suggest that tisotumab vedotin plus frontline carboplatin and second-/third-Line pembrolizumab may be a suitable treatment option for recurrent/metastatic cervical cancer.

Patients with endometrial cancer and high tumor mutational burden experienced superior overall response rates to the agent dostarlimab than patients with low mutational burden.

After the 3-arm, JAVELIN Ovarian 100 trial terminated at the interim analysis, researchers concluded that avelumab is not yet a suitable first-line treatment option for patients with advanced epithelial cancer.

Multidisciplinary approaches are still needed to proactively address the high relapse rates in patients with ovarian cancer treated with platinum-based chemotherapies, says Sanaz Memarzadeh, MD, PhD.

Adherence to current clinical guidelines may contribute to systematic underdiagnosis in Black women, says Kemi M. Doll, MD, MS.

The regulatory decision is based on findings from collective data from the dMMR endometrial cancer cohort A1 and the dMMR solid-tumor, non-endometrial cancer, cohort F of the ongoing phase 1 GARNET trial (NCT02715284).

Nearly half of patients with gynecologic cancer reported financial distress, or financial toxicity, new study says.

The FDA granted a priority review for a Biologics License Application (BLA) to bastilimab for the treatment of recurrent or metastatic cervical cancer.

Adjuvant carboplatin and paclitaxel after standard cisplatin-based chemoradiation did not demonstrate improved overall survival or progression-free survival in patients with locally advanced cervical cancer.

While HPV-related cervical cancer incidence is declining, other tumors related to the virus persist.

Ultimately, the goal is for every eligible patient to receive PARP inhibition in the frontline maintenance setting alone or in combination with bevacizumab, one expert says.

The FDA approved dostarlimab (Jemperli) for the treatment of patients with recurrent or advanced endometrial cancer that progressed on or after platinum-containing chemotherapy and whose cancer is DNA mismatch repair deficient (dMMR), as determined by an FDA-approved test.

Two tests for homologous recombination deficiency have been FDA approved for patients with ovarian cancer, including myChoice CDx and FoundationOne CDx, and they produce important information that can be used to guide treatment decisions.

Maintenance olaparib showcased progression-free survival benefit in almost half of the patients with ovarian cancer vs 21% of those who received placebo, including consistent benefit in high- and low-risk patients.

Robert Wenham, MD, MS, FACOG, FACS, discusses the basis for combining chemotherapy, PARP inhibitors, and VEGF inhibitors with immunotherapy in ovarian cancer and ongoing research with ADCs in the field.

One in 7 Caribbean-born individuals with either breast or ovarian cancer had hereditary disease with an actionable pathogenic variant, which provides the opportunity for the utilization of targeted therapeutics and precise prevention strategies.

The FDA has granted priority review to the new drug application for the novel compound pafolacianine sodium injection for use in the identification of ovarian cancer during surgery.